92 related articles for article (PubMed ID: 24505937)
1. [An inhibitory receptor LMIR3/CD300f recognizes ceramide].
Kitaura J; Izawa K; Kitamura T
Seikagaku; 2013 Dec; 85(12):1071-5. PubMed ID: 24505937
[No Abstract] [Full Text] [Related]
2. The receptor LMIR3 negatively regulates mast cell activation and allergic responses by binding to extracellular ceramide.
Izawa K; Yamanishi Y; Maehara A; Takahashi M; Isobe M; Ito S; Kaitani A; Matsukawa T; Matsuoka T; Nakahara F; Oki T; Kiyonari H; Abe T; Okumura K; Kitamura T; Kitaura J
Immunity; 2012 Nov; 37(5):827-39. PubMed ID: 23123064
[TBL] [Abstract][Full Text] [Related]
3. Sphingomyelin and ceramide are physiological ligands for human LMIR3/CD300f, inhibiting FcεRI-mediated mast cell activation.
Izawa K; Isobe M; Matsukawa T; Ito S; Maehara A; Takahashi M; Yamanishi Y; Kaitani A; Oki T; Okumura K; Kitamura T; Kitaura J
J Allergy Clin Immunol; 2014 Jan; 133(1):270-3.e1-7. PubMed ID: 24035150
[No Abstract] [Full Text] [Related]
4. Disrupting ceramide-CD300f interaction prevents septic peritonitis by stimulating neutrophil recruitment.
Izawa K; Maehara A; Isobe M; Yasuda Y; Urai M; Hoshino Y; Ueno K; Matsukawa T; Takahashi M; Kaitani A; Shiba E; Takamori A; Uchida S; Uchida K; Maeda K; Nakano N; Yamanishi Y; Oki T; Voehringer D; Roers A; Nakae S; Ishikawa J; Kinjo Y; Shimizu T; Ogawa H; Okumura K; Kitamura T; Kitaura J
Sci Rep; 2017 Jun; 7(1):4298. PubMed ID: 28655892
[TBL] [Abstract][Full Text] [Related]
5. Ceramide-CD300f Binding Inhibits Lipopolysaccharide-induced Skin Inflammation.
Shiba E; Izawa K; Kaitani A; Isobe M; Maehara A; Uchida K; Maeda K; Nakano N; Ogawa H; Okumura K; Kitamura T; Shimizu T; Kitaura J
J Biol Chem; 2017 Feb; 292(7):2924-2932. PubMed ID: 28073916
[TBL] [Abstract][Full Text] [Related]
6. Ceramide-CD300f binding suppresses experimental colitis by inhibiting ATP-mediated mast cell activation.
Matsukawa T; Izawa K; Isobe M; Takahashi M; Maehara A; Yamanishi Y; Kaitani A; Okumura K; Teshima T; Kitamura T; Kitaura J
Gut; 2016 May; 65(5):777-87. PubMed ID: 25673319
[TBL] [Abstract][Full Text] [Related]
7. CD300f is a potential therapeutic target for the treatment of food allergy.
Uchida S; Izawa K; Ando T; Yamada H; Uchida K; Negishi N; Kaitani A; Maehara A; Nagamine M; Kamei A; Takamori A; Maeda K; Nakano N; Shimizu T; Ogawa H; Okumura K; Nagahara A; Watanabe S; Kitaura J
Allergy; 2020 Feb; 75(2):471-474. PubMed ID: 31471969
[No Abstract] [Full Text] [Related]
8. An activating and inhibitory signal from an inhibitory receptor LMIR3/CLM-1: LMIR3 augments lipopolysaccharide response through association with FcRgamma in mast cells.
Izawa K; Kitaura J; Yamanishi Y; Matsuoka T; Kaitani A; Sugiuchi M; Takahashi M; Maehara A; Enomoto Y; Oki T; Takai T; Kitamura T
J Immunol; 2009 Jul; 183(2):925-36. PubMed ID: 19561101
[TBL] [Abstract][Full Text] [Related]
9. Mouse LIMR3/CD300f is a negative regulator of the antimicrobial activity of neutrophils.
Ueno K; Urai M; Izawa K; Otani Y; Yanagihara N; Kataoka M; Takatsuka S; Abe M; Hasegawa H; Shimizu K; Kitamura T; Kitaura J; Miyazaki Y; Kinjo Y
Sci Rep; 2018 Nov; 8(1):17406. PubMed ID: 30479367
[TBL] [Abstract][Full Text] [Related]
10. Differential Lipid Recognition by Mouse versus Human CD300f, Inhibiting Passive Cutaneous Anaphylaxis, Depends on a Single Amino Acid Substitution in its Immunoglobulin-Like Domain.
Izawa K; Kaitani A; Ando T; Maehara A; Nagamine M; Yamada H; Ando T; Ide T; Matsuzawa M; Okamoto Y; Yin E; Fukase S; Wang H; Kamei A; Uchida S; Maeda K; Nakano N; Uchida K; Tamura N; Ikeda K; Ebihara N; Shimizu T; Voehringer D; Roers A; Ogawa H; Okumura K; Kitaura J
J Invest Dermatol; 2020 Mar; 140(3):710-713.e3. PubMed ID: 31476319
[No Abstract] [Full Text] [Related]
11. Functional analysis of activating receptor LMIR4 as a counterpart of inhibitory receptor LMIR3.
Izawa K; Kitaura J; Yamanishi Y; Matsuoka T; Oki T; Shibata F; Kumagai H; Nakajima H; Maeda-Yamamoto M; Hauchins JP; Tybulewicz VLJ; Takai T; Kitamura T
J Biol Chem; 2007 Jun; 282(25):17997-18008. PubMed ID: 17438331
[TBL] [Abstract][Full Text] [Related]
12. CD300f associates with IL-4 receptor α and amplifies IL-4-induced immune cell responses.
Moshkovits I; Karo-Atar D; Itan M; Reichman H; Rozenberg P; Morgenstern-Ben-Baruch N; Shik D; Ejarque-Ortiz A; Hershko AY; Tian L; Coligan JE; Sayós J; Munitz A
Proc Natl Acad Sci U S A; 2015 Jul; 112(28):8708-13. PubMed ID: 26124135
[TBL] [Abstract][Full Text] [Related]
13. [LEUKOCYTE MONO-IMMUNOGLOBULIN-LIKE RECEPTOR (LMIR3)-MEDIATED INHIBITION OF ALLERGY AND INFLAMMATION].
Izawa K
Arerugi; 2017; 66(1):36-41. PubMed ID: 28216535
[No Abstract] [Full Text] [Related]
14. Effect of Specific Mutations in Cd300 Complexes Formation; Potential Implication of Cd300f in Multiple Sclerosis.
Martínez-Barriocanal Á; Arcas-García A; Magallon-Lorenz M; Ejarque-Ortíz A; Negro-Demontel ML; Comas-Casellas E; Schwartz S; Malhotra S; Montalban X; Peluffo H; Martín M; Comabella M; Sayós J
Sci Rep; 2017 Oct; 7(1):13544. PubMed ID: 29051512
[TBL] [Abstract][Full Text] [Related]
15. Cis binding between inhibitory receptors and MHC class I can regulate mast cell activation.
Masuda A; Nakamura A; Maeda T; Sakamoto Y; Takai T
J Exp Med; 2007 Apr; 204(4):907-20. PubMed ID: 17420263
[TBL] [Abstract][Full Text] [Related]
16. Disruption of lipid order by short-chain ceramides correlates with inhibition of phospholipase D and downstream signaling by FcepsilonRI.
Gidwani A; Brown HA; Holowka D; Baird B
J Cell Sci; 2003 Aug; 116(Pt 15):3177-87. PubMed ID: 12829737
[TBL] [Abstract][Full Text] [Related]
17. Role of the Ceramide-CD300f Interaction in Gram-Negative Bacterial Skin Infections.
Maehara A; Kaitani A; Izawa K; Shiba E; Nagamine M; Takamori A; Isobe M; Uchida S; Uchida K; Ando T; Maeda K; Nakano N; Voehringer D; Roers A; Shimizu T; Ogawa H; Okumura K; Kitamura T; Kitaura J
J Invest Dermatol; 2018 May; 138(5):1221-1224. PubMed ID: 29221685
[No Abstract] [Full Text] [Related]
18. CD300F blocks both MyD88 and TRIF-mediated TLR signaling through activation of Src homology region 2 domain-containing phosphatase 1.
Lee SM; Kim EJ; Suk K; Lee WH
J Immunol; 2011 Jun; 186(11):6296-303. PubMed ID: 21536801
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of pathologic inflammation by leukocyte Ig-like receptor B4 and related inhibitory receptors.
Katz HR
Immunol Rev; 2007 Jun; 217():222-30. PubMed ID: 17498062
[TBL] [Abstract][Full Text] [Related]
20. Pharmacologic profile of OC000459, a potent, selective, and orally active D prostanoid receptor 2 antagonist that inhibits mast cell-dependent activation of T helper 2 lymphocytes and eosinophils.
Pettipher R; Vinall SL; Xue L; Speight G; Townsend ER; Gazi L; Whelan CJ; Armer RE; Payton MA; Hunter MG
J Pharmacol Exp Ther; 2012 Feb; 340(2):473-82. PubMed ID: 22106101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
